ALLMedicine™ Atrial Flutter Center

Mar 17th, 2023 - The prevalence of atrioventricular conduction disturbance (AVCD) in patients with persistent atrial fibrillation (AF) has not yet been fully investigated. We sought to identify the predictors of AVCD in patients with AF by analyzing the relationsh...

Mar 7th, 2023 - Catheter ablation is recommended as first-line therapy for patients with symptomatic typical AFl. Although the conventional multi-catheter approach is the standard of care for cavotricuspid isthmus (CTI) ablation, a single-catheter approach was re...

Mar 6th, 2023 - Typical atrial flutter ablation involving forming a line of block across the cavotricuspid isthmus in the right atrium has become a commonly performed procedure and is considered a class I indicated procedure for patients who wish to pursue mainte...

Mar 6th, 2023 - Sacubitril/valsartan reduces all-cause mortality in heart failure (HF) patients compared to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). ACEIs/ARBs have been shown to decrease the incidence of atrial f...

Mar 5th, 2023 - A novel ablation catheter has been released to map and ablate the cavo-tricuspid isthmus (CTI) in patients with atrial flutter (AFL), improving ablation efficiency. We evaluated the acute and long-term outcome of CTI ablation aiming at bidirection...

Dec 12th, 2020 - 2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.|2020|Hei...

Feb 19th, 2011 - The stroke rate in atrial fibrillation is 4.5% per year, with death or permanent disability in over half. The risk of stroke varies from under 1% to over 20% per year, related to the risk factors of congestive heart failure, hypertension, age, dia...

Feb 20th, 2008 - ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the...

Mar 6th, 2023 - Typical atrial flutter ablation involving forming a line of block across the cavotricuspid isthmus in the right atrium has become a commonly performed procedure and is considered a class I indicated procedure for patients who wish to pursue mainte...

Mar 1st, 2023 - LUS-AMI is an observational cohort prospective study that evaluates the prognostic value of lung ultrasound, specifically the number of B-lines, performed within the first 24 hours after and ST-segment elevation acute myocardial infarction, by an ...

Feb 28th, 2023 - This is a prospective, open-label, randomized trial to investigate whether a strategy of ongoing, long-term oral anticoagulation with rivaroxaban 15 mg daily is superior to a strategy of antiplatelet therapy, ASA 75-160 mg, alone in preventing cer...

Feb 28th, 2023 - Clinical relevance: The problem of PV reconnection and recurrent AF after catheter ablation for paroxysmal AF is one of the important challenges faced by treating physicians. Rationale: The understanding of the role contact force plays in adequate...

Feb 28th, 2023 - Catheter ablation (CA) for paroxysmal atrial fibrillation (AF) is beset by the significant limitation of recurrent AF in one third of subjects. Subjects with recurrence of AF usually require repeat ablation procedures with the attendant risk of po...

Mar 1st, 2023 - Heart failure patients won't be getting another drug on the market in the form of omecamtiv mecarbil, now that FDA rejected approval of the cardiac myosin activator. The agency thus followed the advice of its Cardiovascular and Renal Drugs Advisor...

Jan 10th, 2023 - Myocarditis associated with mRNA COVID-19 vaccines may be related to circulating free spike antigen, according to a study of antibody profiling and T-cell responses to immunization. (Circulation) Buffalo Bills safety Damar Hamlin's cardiac arrest ...

Dec 13th, 2022 - Omecamtiv mecarbil received a thumbs-down from FDA advisors who complained of its inadequate evidence base during a Cardiovascular and Renal Drugs Advisory Committee meeting on Tuesday. Members voted 8-3 (with no abstentions), stating that the ben...

Dec 12th, 2022 - If omecamtiv mecarbil is to gain a heart failure indication, sponsor Cytokinetics has a lot of convincing to do when the FDA Cardiovascular and Renal Drugs Advisory Committee convenes on Tuesday. FDA advisors will spend the day discussing uncertai...

Nov 4th, 2022 - Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast on Apple Podcasts, Spotify, or your preferred podcast provider...